Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen (AMGN) has outperformed the S&P 500 and its industry over the past month, driven by positive earnings and revenue growth expectations. The consensus EPS estimate points to a 4.9% increase for the current fiscal year and a 2.2% increase for the next, while revenue is projected to grow 5.4% and 1.6% for the same periods, respectively. Despite these positive indicators, Amgen holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market, and is currently trading at a discount to its peers.

Analysis

Amgen (AMGN) has recently demonstrated strong stock performance, with a +6.5% return over the past month, significantly outpacing the Zacks S&P 500 composite's +0.5% change and the Zacks Medical - Biomedical and Genetics industry's +1.3% gain. This investor attention is supported by expectations of continued financial growth; analysts project current quarter earnings of $5.21 per share, a +4.8% year-over-year increase, though the consensus estimate for this period has seen no change in the last 30 days. For the current fiscal year, consensus earnings are forecasted at $20.82 (+4.9% YoY), with a marginal +0.2% upward revision recently, while the next fiscal year anticipates $21.29 EPS (+2.2% YoY) following a +0.3% upward estimate revision in the past month. On the revenue front, current quarter sales are expected to reach $8.86 billion (+5.6% YoY), with full-year projections indicating +5.4% growth for the current fiscal year and a more modest +1.6% for the next. Amgen has a strong track record of exceeding expectations, having beaten consensus EPS estimates in each of the trailing four quarters and revenue estimates three times during that period, exemplified by its last reported quarter where revenues grew +9.4% YoY to $8.15 billion (a +2.47% surprise) and EPS was $4.9 (a +17.79% surprise). Despite these positive metrics and a Zacks Value Style Score of B suggesting it trades at a discount to peers, Amgen carries a Zacks Rank #3 (Hold), indicating its near-term stock performance may align with the broader market.

Key Decisions for Investors

• Investors should weigh Amgen's recent +6.5% stock appreciation and consistent earnings outperformance against its Zacks Rank #3 (Hold), which suggests its stock may perform in line with the market in the near term.
• The company's valuation, indicated as a discount to its peers with a Zacks Value Style Score of B, could present a point of interest for value-oriented investors, despite the neutral near-term outlook.
• Careful monitoring of future earnings reports and estimate revisions is warranted, especially considering the projected deceleration in revenue growth to +1.6% and EPS growth to +2.2% for the next fiscal year, to assess if the current 'Hold' thesis changes.